I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S.

Broadleaf Partners Growth Equity Portfolio returned -11.6% for Q1 2025 vs. the S&P 500 -4.3% return. Click here to read the ...

As Generation Z is entering the workforce, it is prompting companies to adapt, evolve, and innovate, creating a new paradigm ...